Sequential Versus Simultaneous Use of Vinorelbine and Capecitabine in Patients With Metastatic Breast Cancer (MBC)

Breast Cancer Clinical Trial

Official title:

Randomized Multicenter Phase II Study of Sequential Versus Simultaneous Use of Vinorelbine and Capecitabine as First Line Chemotherapy for Patients With Metastatic Breast Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00629148
• Other study ID #: 2007SSVC
• Status: Completed
• Phase: Phase 2
• First received: February 26, 2008
• Last updated: July 6, 2011
• Start date: August 2007
• Est. completion date: December 2010

Study information

• Verified date: June 2011
• Source: Fudan University
• Contact: n/a
• Is FDA regulated: No
• Health authority: China: Ethics Committee
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to evaluate the efficacy and tolerability of sequential use of vinorelbine and capecitabine as first line therapy in patients with MBC.

Description:

The administration of vinorelbine and capecitabine had been implied to be quite useful in metastatic breast cancer. This study was designed to explore whether sequential and simultaneous use of vinorelbine and capecitabine have similar efficacy and whether the sequential way has better tolerability.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: December 2010
• Est. primary completion date: August 2009
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Signed informed consent.

• Female, = 18 and = 70 years.

• Histologically confirmed invasive breast cancer.

• Metastatic breast cancer.

• ECOG Performance Status of 0 to 2.

• Life expectancy of more than 3 months.

• Subject must have adequate organ function.

• Normal laboratory values: hemoglobin > 90g/dl, neutrophils > 1.5×10^9/L, platelets > 80×10^9/L, serum creatinine < 1.5×upper limit of normal (ULN), serum bilirubin < 1.5×ULN, ALT and AST < 2.5×ULN.

• Negative serum pregnancy test for women with childbearing potential.

• Good conditions for infusion and willing to have phlebotomy throughout whole study.

• Have ceased anti-tumor treatments including endocrinotherapy and bio-targeted therapy for more than 28 days.

• Have at least one target lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria.

Exclusion Criteria:

• Pregnant or lactating females

• History of other malignancy. However, subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible

• Concurrent disease or condition that would make the subject inappropriate for study participation, or any serious medical disorder that would interfere with the subject's safety

• Active or uncontrolled infection

• Known history of uncontrolled or symptomatic angina, arrhythmias, or congestive heart failure

• Concomitant with brain metastases

• Have received chemotherapy after metastasis

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms
• Metastasis, Neoplasm
• Neoplasm Metastasis

Intervention

Drug:
• Vinorelbine and Capecitabine
Vinorelbine 25mg/m2 D1, D8 q3w Capecitabine 1000mg/m2 D1-D14 q3w
• Vinorelbine and Capecitabine
Vinorelbine 25mg/m2 D1, D8 q3w. When disease progression or untolerated toxicity occurs, Capecitabine 1000mg/m2 D1-D14 q3w

Locations

Country	Name	City	State
China	Fudan University Cancer Hospital	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Fudan University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	PFS(progression-free survival,defined as the time period between randomization and disease progress or death) and TTF (time to treatment failure, defined as all discontinuations for any cause)	PFS was assessed every two cycles (3 weeks per cycle)and during the follow up time, by serum tumor markers, physical examination and image examination, until disease progression event occurs. If a patient has the sign or hint of disease progression, then the lab examination, physical examination or image examination could be taken at any time.	Every two cycles (3 weeks per cycle) and during the follow up time, until disease progression event occurs.	Yes
Secondary	Safety, QOL(quality of life)	Safety and QOL were assessed every cycle(3 weeks per cycle) and during the follow up time, until 28 days after the last cycle.	Safety and QOL were assessed every cycle and during the follow up time, until 28 days after the last cycle.	Yes
Secondary	TTP(time to progression) and OS (overall survival)	TTP and OS were assessed every cycle(3 weeks per cycle) and during the follow up time, until the event occurs.	TTP and OS were assessed every cycle and during the follow up time, until the event occurs.	Yes